Bevacizumab Plus irinotecan versus temozolomide in newly diagnosed O6-methylguanine-DNA methyltransferase nonmethylated glioblastoma: The randomized GLARIUS trial

Journal of Clinical Oncology

Volumn 34, Issue 14, 2016, Pages 1611-1619

  Herrlinger, Ulrich ^a   Schäfer, Niklas ^a   Steinbach, Joachim P ^b   Weyerbrock, Astrid ^c   Hau, Peter ^d   Goldbrunner, Roland ^e   Friedrich, Franziska ^f   Rohde, Veit ^g   Ringel, Florian ^h   Schlegel, Uwe ^j   Sabel, Michael ^k   Ronellenfitsch, Michael W ^b   Uhl, Martin ^d   Maciaczyk, Jaroslaw ^k   Grau, Stefan ^e   Schnell, Oliver ⁱ   Hänel, Mathias ^l   Krex, Dietmar ^m   Vajkoczy, Peter ⁿ   Gerlach, Rudiger ^o   Kortmann, Rolf Dieter ^f   Mehdorn, Maximilian ^p   Tuttenberg, Jochen ^q   Mayer Steinacker, Regine ^r   Fietkau, Rainer ^s   Brehmer, Stefanie ^t   Mack, Frederic ^a   Stuplich, Moritz ^a   Kebir, Sied ^a   Kohnen, Ralf ^u   Dunkl, Elmar ^u   Leutgeb, Barbara ^v   Proescholdt, Martin ^v   Pietsch, Torsten ^a   Urbach, Horst ^c   Belka, Claus ⁱ   Stummer, Walter ^w   Glas, Martin ^a   more..

^a UNIVERSITY HOSPITAL BONN   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^e UNIVERSITY OF COLOGNE   (Germany)

^f UNIVERSITY OF LEIPZIG   (Germany)

^g UNIVERSITY OF GÖTTINGEN   (Germany)

^h TECHNICAL UNIVERSITY OF MUNICH   (Germany)

ⁱ UNIVERSITY OF MUNICH   (Germany)

^j RUHR UNIVERSITY BOCHUM   (Germany)

^k HEINRICH HEINE UNIVERSITY   (Germany)

^l KLINIKUM CHEMNITZ   (Germany)

^m DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

ⁿ HUMBOLDT UNIVERSITY   (Germany)

^o HELIOS KLINIKUM ERFURT   (Germany)

^p UNIVERSITY OF KIEL   (Germany)

^q Klinikum Idar Oberstein   (Germany)

^r UNIVERSITY OF ULM   (Germany)

^s UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^t UNIVERSITY OF MANNHEIM   (Germany)

^u RPS Research Germany   (Germany)

^v ROCHE INNOVATION CENTER MUNICH   (Germany)

^w UNIVERSITY OF MÜNSTER   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; IRINOTECAN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DACARBAZINE; DNA LIGASE; DNA METHYLTRANSFERASE; MGMT PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ARTICLE; ASSESSMENT OF HUMANS; BLOOD TOXICITY; BRAIN HEMORRHAGE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; COGNITION; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER QUALITY OF LIFE QUESTIONNAIRE; FEMALE; GLIOBLASTOMA; HUMAN; HYPERTENSION; INTENTION TO TREAT ANALYSIS; KARNOFSKY PERFORMANCE STATUS; LUNG EMBOLISM; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NAUSEA AND VOMITING; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DNA METHYLATION; ENZYMOLOGY; GENETICS; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PROMOTER REGION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CAMPTOTHECIN; DACARBAZINE; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; PROMOTER REGIONS, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 84969921399     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.63.4691     Document Type: Article

References (25)

1. Stupp R, Hegi ME, Mason WP, et al: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459-466, 2009.
2. Hegi ME, Diserens AC, Gorlia T, et al: MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003, 2005.
3. Wick W, Steinbach JP, Platten M, et al: Enzastaurin before and concomitant with radiation therapy, followed by enzastaurin maintenance therapy, in patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation. Neurooncol 15:1405-1412, 2013.
4. Plate KH, Breier G, Weich HA, et al: Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359:845-848, 1992.
5. Berkman RA, Merrill MJ, Reinhold WC, et al: Expression of the vascular permeability factor/vascular endothelial growth factor gene in central nervous system neoplasms. J Clin Invest 91:153-159, 1993.
6. Vredenburgh JJ, Desjardins A, Herndon JE II, et al: Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. J Clin Oncol 25:4722-4729, 2007.
7. Friedman HS, Prados MD, Wen PY, et al: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733-4740, 2009.
8. Kreisl TN, Kim L, Moore K, et al: Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740-745, 2009.
9. ChinotOL, WickW, MasonW, et al:Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709-722, 2014.
10. Gilbert MR, Dignam JJ, Armstrong TS, et al: A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699-708, 2014.
11. Prados MD, Lamborn K, Yung WK, et al: A phase II trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: A North American Brain Tumor Consortium study. Neuro-oncol 8:189-193, 2006.
12. Vlassenbroeck I, Califice S, Diserens AC, et al: Validation of real-time methylation-specific PCR to determine O6-methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 10:332-337, 2008.
13. Stupp R, Hegi ME, Gorlia T, et al: Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): A multicentre, randomised, open-label, phase III trial. Lancet Oncol 15:1100-1108, 2014.
14. Schouten HJ: Adaptive biased urn randomization in small strata when blinding is impossible. Biometrics 51:1529-1535, 1995.
15. Macdonald DR, Cascino TL, Schold SC Jr, et al: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277-1280, 1990.
16. Osoba D, Aaronson NK, Muller M, et al: The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res 5:139-150, 1996.
17. Folstein MF, Folstein SE, McHugh PR: Minimental state: A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12:189-198, 1975.
18. Fleiss JL, Tytun A, Ury HK: A simple approximation for calculating sample sizes for comparing independent proportions. Biometrics 36:343-346, 1980.
19. White IR: Uses and limitations of randomizationbased efficacy estimators. Stat Methods Med Res 14: 327-347, 2005.
20. White IR: Estimating treatment effects in randomized trials with treatment switching. Stat Med 25:1619-1622, 2006.
21. Demetri GD, Garrett CR, Schoffski P, et al: Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure. Clin Cancer Res 18:3170-3179, 2012.
22. Robins JM, Tsiatis A: Correcting for noncompliance in randomized trials using rank-preserving structural failure time models. Commun Stat Theory Methods 20:2609-2631, 1991.
23. Kurland BF, Johnson LL, Egleston BL, et al: Longitudinal data with follow-up truncated by death: Match the analysis method to research aims. Stat Sci 24:211-222, 2009.
24. Nabors LB, Fink KL, Mikkelsen T, et al: Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: Results of the open-label, controlled, randomized, phase II CORE study. Neuro-oncol 17:708-717, 2015.
25. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005.